Activist investor Ananym Capital Management is urging healthcare products distributor Henry Schein to refresh its board, cut costs, tackle succession planning and consider selling its medical ...
Robert W. Baird analyst Jeff Johnson reiterated a Buy rating on Henry Schein (HSIC – Research Report) on November 5 and set a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback